European Commission grants marketing authorization for new subcutaneous administration of natalizumab to treat relapsing-remitting multiple sclerosis

Approval of new route of administration is based on data from the DELIVER and REFINE studies, which showed comparability to 4-weekly IV administration of 300mg dose in efficacy, pharmacokinetic and pharmacodynamic profiles.

Source:

Biospace Inc.